MX2020004566A - Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso. - Google Patents
Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso.Info
- Publication number
- MX2020004566A MX2020004566A MX2020004566A MX2020004566A MX2020004566A MX 2020004566 A MX2020004566 A MX 2020004566A MX 2020004566 A MX2020004566 A MX 2020004566A MX 2020004566 A MX2020004566 A MX 2020004566A MX 2020004566 A MX2020004566 A MX 2020004566A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- calreticulin
- interactions
- shared epitope
- methods
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title abstract 3
- 150000003384 small molecules Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010051728 Bone erosion Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004957 immunoregulator effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se encuentra en el campo de la química medicinal. En particular, la invención se refiere a una clase nueva de moléculas pequeñas con una estructura de triazol-metil piperidinil-pirolil-propenona que funcionan como moduladores de la interacción y/o unión de epítopo compartido (SE) - calreticulina (CRT), y su uso como agentes terapéuticos para el tratamiento de anomalías inmunorreguladoras (por ejemplo, enfermedades autoinmunitarias, enfermedades inflamatorias (por ejemplo, enfermedad inflamatoria crónica) y enfermedades de erosión ósea) al inhibir de forma selectiva las interacciones de SE-CRT y/o las vías de transducción de señales comúnmente hiperactivas o desreguladas en las enfermedades o afecciones artríticas y/u otras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582584P | 2017-11-07 | 2017-11-07 | |
| PCT/US2018/059623 WO2019094469A1 (en) | 2017-11-07 | 2018-11-07 | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004566A true MX2020004566A (es) | 2020-08-13 |
Family
ID=66326814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004566A MX2020004566A (es) | 2017-11-07 | 2018-11-07 | Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso. |
| MX2022016067A MX2022016067A (es) | 2017-11-07 | 2020-07-13 | Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016067A MX2022016067A (es) | 2017-11-07 | 2020-07-13 | Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10723718B2 (es) |
| EP (1) | EP3706744B1 (es) |
| JP (1) | JP2021502361A (es) |
| KR (1) | KR20200085278A (es) |
| CN (2) | CN111315383B (es) |
| AU (1) | AU2018366022B2 (es) |
| CA (1) | CA3079848A1 (es) |
| MX (2) | MX2020004566A (es) |
| WO (1) | WO2019094469A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019094469A1 (en) * | 2017-11-07 | 2019-05-16 | The Regents Of The University Of Michigan | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
| CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
| CN112125561B (zh) * | 2020-09-18 | 2021-11-02 | 河海大学 | 一种基于植物花粉提取液的水泥基材料调热缓凝剂、制备方法及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552891A (en) | 1983-09-13 | 1985-11-12 | Eli Lilly And Company | Benzothiophene derivatives |
| GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
| GB9102579D0 (en) | 1991-01-24 | 1991-03-27 | Glaxo Group Ltd | Compositions |
| BE1007839A6 (nl) | 1993-12-20 | 1995-10-31 | Merkus Franciscus W H M Prof | Farmaceutische compositie voor de nasale toediening van hydroxocobalamine. |
| US5864037A (en) | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
| US6124319A (en) * | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| US6878700B1 (en) | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| UA74781C2 (en) * | 1999-04-02 | 2006-02-15 | Abbott Lab | Antiinflammatory and immumosuppressive compounds inhibiting cell adhesion |
| US7208154B2 (en) * | 2002-06-03 | 2007-04-24 | Regents Of The University Of Michigan | Methods and compositions for the treatment of MHC-associated conditions |
| US7074893B2 (en) | 2002-06-03 | 2006-07-11 | Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US20050138290A1 (en) | 2003-12-23 | 2005-06-23 | Intel Corporation | System and method for instruction rescheduling |
| PT3077395T (pt) * | 2013-12-05 | 2018-01-03 | Pfizer | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas |
| WO2019094469A1 (en) * | 2017-11-07 | 2019-05-16 | The Regents Of The University Of Michigan | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
-
2018
- 2018-11-07 WO PCT/US2018/059623 patent/WO2019094469A1/en unknown
- 2018-11-07 CN CN201880071416.9A patent/CN111315383B/zh active Active
- 2018-11-07 US US16/183,309 patent/US10723718B2/en active Active
- 2018-11-07 CN CN202311174646.7A patent/CN117304172A/zh active Pending
- 2018-11-07 MX MX2020004566A patent/MX2020004566A/es unknown
- 2018-11-07 KR KR1020207012957A patent/KR20200085278A/ko not_active Application Discontinuation
- 2018-11-07 EP EP18875370.1A patent/EP3706744B1/en active Active
- 2018-11-07 AU AU2018366022A patent/AU2018366022B2/en active Active
- 2018-11-07 JP JP2020524852A patent/JP2021502361A/ja active Pending
- 2018-11-07 CA CA3079848A patent/CA3079848A1/en active Pending
-
2020
- 2020-06-09 US US16/896,546 patent/US11168071B2/en active Active
- 2020-07-13 MX MX2022016067A patent/MX2022016067A/es unknown
-
2021
- 2021-10-14 US US17/501,572 patent/US11613528B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11168071B2 (en) | 2021-11-09 |
| AU2018366022A1 (en) | 2020-04-30 |
| US10723718B2 (en) | 2020-07-28 |
| KR20200085278A (ko) | 2020-07-14 |
| CN111315383B (zh) | 2023-09-29 |
| JP2021502361A (ja) | 2021-01-28 |
| EP3706744B1 (en) | 2022-08-17 |
| CA3079848A1 (en) | 2019-05-16 |
| AU2018366022B2 (en) | 2024-05-16 |
| US20200299268A1 (en) | 2020-09-24 |
| EP3706744A4 (en) | 2020-12-09 |
| US11613528B2 (en) | 2023-03-28 |
| CN117304172A (zh) | 2023-12-29 |
| MX2022016067A (es) | 2023-02-02 |
| CN111315383A (zh) | 2020-06-19 |
| EP3706744A1 (en) | 2020-09-16 |
| WO2019094469A1 (en) | 2019-05-16 |
| US20220106292A1 (en) | 2022-04-07 |
| US20190135783A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| AR107781A1 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| ECSP19021312A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos | |
| ECSP17064695A (es) | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 | |
| CO2018013077A2 (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
| BR112018003212A2 (pt) | diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| BR112015021495A2 (pt) | fabricação contínua integrada de substâncias de droga de proteína terapêutica | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| BR112013017988A2 (pt) | inibidores de bace-2 para o tratamento de distúrbios metabólicos | |
| CR20150604A (es) | Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos | |
| CR20150390A (es) | Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2) | |
| BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
| MX2020004566A (es) | Inhibidores de molécula pequeña de interacciones de epítopo compartido-calreticulina y métodos de uso. | |
| GT201600027A (es) | Inhibidores de rorc2 y sus métodos de uso | |
| CL2017000715A1 (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| CR20160133A (es) | Derivados de fenilalanina sustituidos | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний |